Dark

AKBA
Akebia Therapeutics, Inc.
stock NASDAQ

Market Open

Jul 16, 2025 3:01:30 PM EDT

3.90USD+0.515%(+0.02)1,387,253

3.89Bid 3.90Ask 0.01Spread

Pre-market

Jul 16, 2025 8:50:30 AM EDT

3.88USD0.000%(0.00)12,307

After-hours

Jul 15, 2025 4:24:30 PM EDT

3.89USD+0.387%(+0.02)0

OverviewOptionsHistoricalExchangesShortsMore

open chart

Market Cap

1.02B

CEO

John Butler

Headquarters

Cambridge, Massachusetts, USA

Industry

Biotechnology

Next Earnings

Jul 31, 2025 (15d)

AMGN KERX NKTR NVS JNJ XLV

AKBA Stats

Avg. Vol. 10 Day

3,474,721

Avg. Vol. 30 Day

5,424,001

Employees

114

Market Cap

1,024,279,760

Shares Out.

262,635,836

On/Off Exchange

46%/54%

6 Month Beta

1.07

1 Year Beta

1.28

2 Year Beta

1.28

3 Year Beta

1.37

52 Week Low

1.07

52 Week High

4.08

SMA50

3.28

SMA200

2.24

1 Week

-2.26%

1 Month

+8.94%

3 Month

+105.26%

6 Month

+102.07%

1 Year

+174.65%

2 Year

+225.00%

5 Year

-68.24%

Profile

akebia therapeutics, inc. is a biopharmaceutical company headquartered in cambridge, massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor (hif) biology. akebia's lead product candidate, vadadustat, is an investigational oral therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. akebia's global phase 3 program for vadadustat, which includes the pro2tect studies for non-dialysis patients with anemia associated with chronic kidney disease and the inno2vate studies for dialysis-dependent patients, is currently ongoing. for more information, please visit our website at www.akebia.com.

AKBA Stock Summary

Akebia Therapeutics, Inc. (NASDAQ:AKBA) stock price today is $3.90, and today's volume is 1,387,253. AKBA is up 0.515% today. The 30 day average volume is 5,424,001. AKBA market cap is 1.02B with 262,635,836 shares outstanding.